Article
Genetic association with response to intravitreal ranibizumab in patients with neovascular AMD.
Investigative ophthalmology & visual science - 1 Jul 2011
Kloeckener-Gruissem Barbara, Barthelmes Daniel, Labs Stephan, Schindler Christian, Kurz-Levin Malaika, Michels Stephan, Fleischhauer Johannes, Berger Wolfgang, Sutter Florian, Menghini Moreno
Abstract excerpt
PURPOSE: Neovascular age-related macular degeneration (AMD) resulting in decreased central vision severely impairs affected individuals. Current standard treatment is an intravitreal anti-VEGF therapy (ranibizumab), but responses to treatment show large variability. Genetic factors that influence AMD and that affect the outcome of ranibizumab treatment were sought within a sample of Swiss patients. METHODS:...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.